Detalhe da pesquisa
1.
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.
J Infect Dis
; 227(1): 123-132, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108079
2.
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
Gut
; 71(8): 1629-1641, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34493592
3.
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.
Hepatol Commun
; 7(8)2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459199
4.
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.
Aliment Pharmacol Ther
; 56(2): 310-320, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35521992